ArticleBMC public health2025
Global burden of cystic echinococcosis: a 32-year analysis of 204 countries with 2036 projections.
Article in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Prevalence and Genetic Diversity ofBiology · 2026Article
- Diagnostic Pathways and Genotyping of Cases ofPathogens (Basel, Switzerland) · 2026Article
- Global Comparative Phylogeography of E. granulosus s.s. Inferred From Mitochondrial DNA: Integrated Datasets of GenBank and Newly Characterized Isolates From Afghanistan.Transboundary and emerging diseases · 2026Article
- Primary hydatid cyst of the parapharyngeal space: a rare head and neck presentation.Journal of surgical case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCystic echinococcosis (CE), a neglected zoonotic disease, remains a significant public health challenge in low- and middle-income regions. This study systematically evaluates the global, regional, and national burden of CE from 1990 to 2021 and projects trends to 2036 using data from the Global Burden of Disease Study 2021.
methodsWe analyzed age-standardized prevalence (ASPR), incidence (ASIR), mortality (ASMR), and disability-adjusted life years (ASDR) across 204 countries, stratified by Socio-demographic Index (SDI). Decomposition analysis assessed contributions of population aging, growth, and epidemiological changes. An autoregressive integrated moving average (ARIMA) model projected future disease burden.
resultsGlobally, ASPR increased slightly from 7.37 to 7.69 per 100,000 (EAPC = 0.31%, 95% CI: 0.15%-0.47%) between 1990 and 2021, while ASMR declined sharply (EAPC = - 4.83%, 95% CI: -4.90%--4.76%). Low-SDI regions bore the highest burden (ASPR = 9.88 vs. 1.67 per 100,000 in high-SDI regions). Middle-aged populations (45-69 years) and females faced disproportionate risks. Projections indicate stable ASPR/ASIR but declining ASMR/ASDR by 2036. Regional disparities persisted, with Southern Latin America and Central Asia having the highest prevalence.
conclusionsDespite progress in mortality reduction, CE burden remains elevated in low-resource settings. Prioritizing interventions in low-SDI regions, adults aged 45-69 years, and women, alongside One Health strategies, is critical to narrowing inequities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.